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Background: Given the rarity of most single-gene Mendelian disorders, concerted efforts of data exchange
between clinical and scientific communities are critical to optimize molecular diagnosis and novel disease
gene discovery.
Methods: We designed and implemented protocols for the study of cases for which a plausible molecular
diagnosis was not achieved in a clinical genomics diagnostic laboratory (i.e. unsolved clinical exomes). Such
cases were recruited to a research laboratory for further analyses, in order to potentially: (1) accelerate novel
disease gene discovery; (2) increase the molecular diagnostic yield of whole exome sequencing (WES); and
(3) gain insight into the genetic mechanisms of disease. Pilot project data included 74 families, consisting
mostly of parent–offspring trios. Analyses performed on a research basis employed both WES from additional
family members and complementary bioinformatics approaches and protocols.
Results: Analysis of all possible modes of Mendelian inheritance, focusing on both single nucleotide variants
(SNV) and copy number variant (CNV) alleles, yielded a likely contributory variant in 36% (27/74) of cases. If
one includes candidate genes with variants identified within a single family, a potential contributory variant
was identified in a total of ~51% (38/74) of cases enrolled in this pilot study. The molecular diagnosis was
achieved in 30/63 trios (47.6%). Besides this, the analysis workflow yielded evidence for pathogenic variants in
disease-associated genes in 4/6 singleton cases (66.6%), 1/1 multiplex family involving three affected siblings,
and 3/4 (75%) quartet families. Both the analytical pipeline and the collaborative efforts between the
diagnostic and research laboratories provided insights that allowed recent disease gene discoveries (PURA,
TANGO2, EMC1, GNB5, ATAD3A, and MIPEP) and increased the number of novel genes, defined in this study
as genes identified in more than one family (DHX30 and EBF3).
(Continued on next page)* Correspondence: jlupski@bcm.edu
†Equal contributors
1Department of Molecular and Human Genetics, Baylor College of Medicine,
Houston, TX 77030, USA
8Texas Children’s Hospital, Houston, TX 77030, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Eldomery et al. Genome Medicine  (2017) 9:26 Page 2 of 15(Continued from previous page)
Conclusion: An efficient genomics pipeline in which clinical sequencing in a diagnostic laboratory is followed
by the detailed reanalysis of unsolved cases in a research environment, supplemented with WES data from
additional family members, and subject to adjuvant bioinformatics analyses including relaxed variant filtering
parameters in informatics pipelines, can enhance the molecular diagnostic yield and provide mechanistic
insights into Mendelian disorders. Implementing these approaches requires collaborative clinical molecular
diagnostic and research efforts.Background
Applications to clinical practice of whole exome sequen-
cing (WES) and whole genome sequencing (WGS)
technologies and the computational interpretation of
rare variants in genome data have been revolutionary,
allowing conclusions to diagnostic odysseys and enabling
molecular diagnoses for thousands of patients [1–7].
Moreover, such genome-wide assays have enabled insights
into multi-locus contributions to disease [8]. Recent re-
ports document an initial ~25–30% rate of molecular
diagnosis in known disease genes for patients referred
for exome sequencing and interpretation [3, 5, 9–12].
The remaining undiagnosed individuals may represent:
(1) limitations in concluding a molecular diagnosis
using the current experimental and analytical methods
of clinical genomics practice; or (2) our limited under-
standing of the genetics of human disease. Collabor-
ation between the clinical, clinical molecular diagnostic,
and research communities may optimize discovery of
disease genes, considering the rarity of specific genetic
disorders [13–17].
We performed a pilot study for systematic transfer of
molecularly “unsolved” exomes from the clinical envir-
onment to a research setting, in order to potentially fuel
human genetic disease gene discovery. The WES data
from 74 probands for whom clinical singleton WES did
not reveal a secure molecular diagnosis were augmented
with WES from additional family members, where avail-
able. Additional bioinformatics filters, database re-
sources, and interpretive analyses were implemented,
leveraging systematic studies emerging from the research
laboratory. A likely disease contributory gene and poten-
tial molecular diagnosis (i.e. known disease gene or
novel gene identified in more than one family) was iden-
tified in 36% of the probands, and a candidate gene find-
ing (i.e. identified in a single family) was identified in
15% of patients. This experience and resulting findings
offer the opportunity to systematically compare different
but complementary approaches to optimize molecular
diagnostic yield. Several novel gene discoveries (PURA,
TANGO2, EMC1, GNB5, ATAD3A, MIPEP) [18–23]
were facilitated by this collaborative and systematic clin-
ical/research laboratory approach, and additional novel
disease genes were found in multiple families (DHX30,EBF3), together highlighting different genetic contribu-
tions to pathogenicity [24–26].
Methods
Recruitment of non-diagnostic clinical exome cases into
research
Probands, whose DNA had been analyzed at Baylor
Genetics (BG) laboratory for clinical diagnostic WES,
and for whom a molecular diagnosis (defined as a patho-
genic or likely pathogenic variant according to American
College of Medical Genetics and Genomics [ACMG]
guidelines) was not achieved at the time of initial report-
ing, were classified as “unsolved” and enrolled into the
study [3, 27]. For this pilot study, a total of 74 unsolved
clinical WES cases, analyzed by the clinical genomics
laboratory between April 2012 and April 2014, were
enrolled in research between July 2013 and March 2015.
Enrollment proceeded in serial order with no specific
inclusion or exclusion criteria, other than the inability to
achieve a molecular diagnosis in the clinical genomics
laboratory and parents consenting to research analyses.
Depending on the clinical situation and individual avail-
ability, additional family members (e.g. parents or
affected siblings) were also enrolled.
Our pilot study consisted of 74 cases including 63
trios, four quartets, one multiplex family involving three
affected siblings, and six singleton cases for which par-
ental samples were unavailable. Prior diagnostic work-up
was variable from case to case based on the referring
physician’s differential diagnosis (e.g. single gene testing,
enzyme assays, array comparative-genome hybridization)
and included a proband-only WES in all cases. Mito-
chondrial DNA sequencing was performed for all cases
undergoing clinical WES through December 2014. De-
tailed clinical phenotype data were collected and entered
into PhenoDB [14, 28], after contacting the families/
patients to obtain informed consent, and did not influ-
ence the choice of cases. However, we retrospectively
analyzed the phenotypic features of this cohort and
found that developmental delay/intellectual disability
(DD/ID) was the most prevalent phenotype in our pilot
study, consistent with the nature of cases referred for
clinical WES [3, 5]. Our phenotypic analysis revealed
59 cases with syndromic DD/ID and one with non-
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encountered in the 74 cases of the pilot study were
metabolic, gastrointestinal, and mitochondrial abnormal-
ities (Additional file 1: Table S1).
Whole exome sequencing and annotation
Exome capture was performed with Nimblegen reagents
using the Baylor College of Medicine (BCM) Human
Genome Sequencing Center (HGSC) custom-designed
capture reagent VCRome 2.1 for both clinical and re-
search laboratory exomes. This capture reagent contains
more than 196K targets and 42 Mbp of genomic regions
and includes predicted coding exons from Vega, CCDS,
and RefSeq. Samples are multiplexed (six-plex format)
for both capture and sequencing and full-length blocking
oligos were employed for hybridization to enhance on-
target specificity [3, 5, 29]. Clinical WES targets the cod-
ing exons of ~20,000 genes with 130X average depth of
coverage and greater than 95% of the targeted bases
having >20 reads [3, 5, 29, 30]. Research WES (for add-
itional family members) had an average depth of cover-
age of 95X, with >92% of the targeted bases having >20
reads. The raw sequence data were post-processed using
the Mercury pipeline [31]. First, the raw sequencing data
(bcl files) were converted to fastq files using Casava.
Then, the Burrows-Wheeler Alignment (BWA) tool was
utilized to map short reads to the human genome refer-
ence sequence (GRCh37). Finally, the recalibration and
variant calling were performed using GATK [30] and the
Atlas2 suite, respectively [32]. The Mercury pipeline is
available in the cloud via DNANexus (http://blog.dna-
nexus.com/2013-10-22-run-mercury-variant-calling-pipe-
line/). For research cases, exome variant analyses were
then independently performed in the Baylor Hopkins
Center for Mendelian Genomics (BHCMG) [15] under a
Research Protocol approved by the Institutional Review
Board (IRB) for Human Subjects Research at BCM; this
protocol enables bi-directional transfer of samples and
data between the clinical and research laboratories.
Identification of de novo single nucleotide variants (SNVs)
in BHCMG
De novo variants were identified by an in-house developed
software called DNM (de novo mutation)-Finder (https://
github.com/BCM-Lupskilab/DNM-Finder), available upon
request. Parental variants were subtracted in silico from
the proband’s variants in vcf files, while incorporating
read number information extracted from BAM files.
Filtering was then implemented using the following
criteria: (1) an alternative variant read count greater
than 5 in the proband; (2) ratio of alternative variant
read count to reference variant read count greater
than 30% in the proband; (3) reference variant read
count greater than 10 in both parents; and (4) ratioof alternative variant read count to reference variant
read count less than 5% in both parents.SNV prioritization and filtering workflow
We designed a stepwise analysis workflow. This workflow
consists of four major steps of analysis that examined: (1)
recessive homozygous predicted loss-of-function (LOF) var-
iants (stop-gain, frameshift indels, and splice site variants)
and/or missense variants; (2) compound heterozygous LOF
and/or missense variants; (3) heterozygous LOF variants,
which facilitated the detection of potential truncating de
novo mutations in proband-only WES cases; and (4) de
novo variants and potential parental mosaic variants using
trio-WES (Fig. 1a). Variants were prioritized for further
study based on their minor allele frequencies (MAF; <0.5%)
and the output from several prediction software algorithms
that identified cross-species conservation or variant effects
on protein function (Fig. 1a) [33]. Subsequently, each vari-
ant was further filtered based on additional gene and
variant-level information from publicly available databases:
Online Mendelian Inheritance in Man (OMIM: http://
www.omim.org); PubMed; the Human Gene Mutation
Database (HGMD: http://www.hgmd.cf.ac.uk); and ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/). This sequential
analysis eliminates the bias towards a particular mode of in-
heritance, mutation type, and the prior knowledge of the
role of a specific gene in human disease. Additionally, this
approach also integrates the fundamentals of WES analysis
based on previously described SNV workflows and is com-
patible with ACMG guidelines for SNV filtering and classi-
fication of variant pathogenicity [3, 9, 27]. Analysis of
interactomes, gene families, protein–protein interactions,
co-expression data, and available literature further priori-
tized candidate variants (Fig. 1b). The patterns of segrega-
tion of the remaining candidate variants were analyzed by
Sanger sequencing in available family members. Finally,
the most promising candidate genes/variants were used to
interrogate local databases and GeneMatcher [13, 14] to
find additional affected cases with damaging variants in
the same gene and with similar clinical phenotypes. When
the BHCMG identified suspected causative variants in ei-
ther newly discovered or recently published known
disease genes, it was communicated to the clinical ex-
ome laboratory. Sanger confirmation of the suspected
pathogenic variant was performed for all of the identified
variants (confirmation rate of 100%) under the aus-
pices of the CAP/CLIA-certified diagnostic laboratory
and a formal updated clinical report was issued. Simi-
larly, identified variants both in novel genes and in re-
cent reports from the clinical exome laboratory were
reported back to BHCMG, creating a bidirectional
channel of intercommunication between research and
clinical laboratories.
Fig. 1 Analysis of WES data. a SNVs were filtered and prioritized according to specific criteria, including mode of inheritance, mutation type,
variant frequency, conservation, and predictions of pathogenicity. b Candidate genes were further prioritized by data mining, taking into
consideration gene function, expression, and networks. In addition, other cohorts were interrogated for additional families with variants in the
same candidate gene. MutationMapper (http://www.cbioportal.org/mutation_mapper.jsp), ARIC Atherosclerosis Risk in Communities Study, AR-
Hom autosomal recessive-homozygous, BHCMG Baylor-Hopkins Center for Mendelian Genomics, BG Baylor Genetics laboratories, CNV copy number
variation, Comp compound, db database, ExAC Exome Aggregation Consortium, Het heterozygous, HGMD Human Gene Mutation Database, MAF minor
allele frequency; SNV single nucleotide variant, XLR-Hem X-linked recessive-hemizygous
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of “bulk data” in order to accelerate our WES data
analyses by scanning the BHCMG database for rare
homozygous/heterozygous stop-gain variants culled from
WES data of ~5000 research participants including our
pilot study cases. In this analysis, we targeted the rare
(MAF <0.5%) homozygous stop-gain variants from ~5000
research participants (including the 74 families) for
each gene. Genes were then sorted according to the
number of homozygous rare stop-gain variants exist-
ing in our database. Second, the genes were analyzed
further according to SNV prioritization and filtering
workflow as described above (Fig. 1). This approach
was designed to accelerate the discovery of noveldisease genes that exhibit phenotypic consequences
through a loss-of-function mechanism.
Detection of CNVs
CNV detection from WES data has been employed by dif-
ferent clinical laboratories to improve the molecular diag-
nostic rate [34, 35]. We applied several computational
algorithms (CoNVex, Sanger Centre [ftp://ftp.sanger.ac.uk/
pub/users/pv1/CoNVex/Docs/CoNVex.pdf], CoNIFER, and
XHMM) to WES data to identify potential disease associ-
ated CNVs; these tools detect a clinically relevant intra-
genic CNV when at least three contiguous exons are
deleted [36, 37]. Therefore, in addition to these algo-
rithms, we developed an in-house pipeline HMZDelFinder
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to detect potential homozygous and hemizygous small in-
tragenic deletions from WES data, including single exon
“dropout alleles” that may be less robustly identified by
current software.
Results
The findings were sorted into three major categories: (1)
known disease genes; (2) novel genes: genes with pre-
dicted pathogenic variants in two or more cases with
similar phenotypes; and (3) potential candidate genes:
genes with variants in a single case (Table 1). Predicted
pathogenic variants in known or novel disease genes
were identified in 27/74 (36%) families studied. In
addition, predicted pathogenic variants in candidate
genes were identified in 11/74 (15%) of cases, yielding an
overall potential solved rate of 38/74 (51%) of cases. Our
findings are represented by six “lessons learned” clusters:
(1) de novo changes in known genes; (2) de novo
changes in novel and candidate genes; (3) potential
mosaicism in parents; (4) biallelic or hemizygous vari-
ants in genes known to convey recessive disease traits;
(5) biallelic variants in novel and candidate recessive
disease genes; and (6) blended phenotypes resulting
from dual molecular diagnoses (Fig. 2a, b). Examples for
each of these scenarios are presented below.
De novo changes in known genes
Analysis of WES data from sets of parents and offspring
initially yielded ~50–200 putative de novo variants per
trio. Further prioritization, based upon read coverage,
MAF and mutation type (non-synonymous, stop-gain,
frameshift indels, and splicing variants), reduced the
number of potential pathogenic de novo variants per
family to ~0–5 variants per proband (Additional file 2:
Figure S1). We detected de novo variants in five recently
published genes (Table 1, Additional file 3: Table S2):
ZBTB20 associated with Primrose syndrome [39] (MIMTable 1 Molecular diagnoses in 74 cases are represented as three ma
Inheritance Known genes Nove
De novo CACNA1A, DDX3X(X2)a, NALCN(X2),
NR2F1a, ZBTB20
ATAD3
Autosomal/X-linked Recessive ABCA4, DDX3X, FBXL4a, NAA10,
SLC13A5a (X2), TRAPPC11, ZNF335a
GNB5
Other NA
UPD SLC1A4a
Mosaic PIK3CD
Dual molecular diagnosis PMPCA + KCND3a
POLRIC + SCNIBa
aCases independently solved by the clinical exome laboratory re-analysis
Three major categories of identified genes include 13 candidate genes identified in
families had more than one molecular diagnosis (indicated by PMPCA + KCND3, POL
identified in more than one family (indicated by “(X2)” in the table)
NA non-applicable259050); NR2F1 causing the Bosch-Boonstra-Schaaf
optic atrophy syndrome [40] (MIM 615722); DDX3X
associated with X-linked intellectual disability [41]
(MIM 300958); CACNA1A implicated in non-fluctuating
ataxia [42]; and NALCN associated with congenital con-
tractures of the limbs and face, hypotonia, and develop-
mental delay [43] (MIM 616266).
De novo changes in novel and candidate genes
We further identified de novo variants in five novel and
ten candidate genes (Table 1, Additional file 3: Table S2).
A de novo SNV in DHX30 c.2344C > T (p.Arg782Trp)
was found in a patient with microcephaly, developmen-
tal delay/intellectual disability (DD/ID), mild cerebral
volume loss, hypotonia, seizures, short stature, failure to
thrive, and generalized hirsutism. Through data ex-
change [3, 5] with the clinical exome laboratory (Baylor
Genetics) and GeneMatcher [13, 14], we found three
additional unrelated participants with overlapping fea-
tures, each of whom harbored a de novo SNV in
DHX30. Interestingly, two of these participants shared
the same de novo SNV c.2344C > T, occurring at a CpG
dinucleotide (Fig. 3a) [44]. DEAH (Asp-Glu-Ala-His)
box helicase 30 (DHX30, MIM 616423) is a member of
the RNA helicase family including DHX and DDX pro-
teins involved in DNA transcription, splicing and trans-
lation [45–47], and is highly expressed in the brain
during neurogenesis [45]. Homozygous knockout of
Dhx30 in mice is lethal [45]. DDX3X, another member
of this family, has been recognized recently to play a
major role in DD/ID [41]. Additionally, DHX37 has been
proposed as a candidate gene for brain malformations
[48], highlighting the importance of RNA helicases in
development of the central nervous system.
GSPT2 and EBF3 each harbored one de novo variant
in the genomes from two separate probands (Table 1,
Additional file 3: Table S2). Each of these genes
is located within CNV intervals identified previouslyjor categories: known genes, novel genes and candidate genes
l genes Candidate genes
A, DHX30, EBF3, EMC1, PURAa CDK20 + HIVEP1, DNAH7, GSPT2 GUCY2C,
MICALL2 + SLC30A7, MPP4, SYN3, SYTL2
, MIPEP, TANGO2a ACOT1a, NRXN3, USP19
NA
11 families and 26 known or novel genes in 27 families. Note that some
R1C + SCN1B, CDK20 + HIVEP1, MICALL2 + SLC30A7) and some genes were
Fig. 2 Overview of the study design and results. a Clinical WES cases that lacked a definitive molecular diagnosis (left) were eligible for
recruitment into a research environment. In a pilot study of 74 families (right), we identified strong candidate genes for 51% (38/74) of cases.
Identified variants were categorized into six major classes based on mode of inheritance and known or novel gene. b According to stringent
criteria, a potential contributory variant was achieved in 27 of 74 (36%) cases. Of these, 12 were independently solved by the clinical exome
laboratory upon reanalysis of WES data and updated literature review. When taking into account strong candidate genes identified in only a
single family to date, a potential molecular diagnostic rate of 51% was achieved
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for their roles in neurodevelopmental phenotypes
(Additional file 4: Supplemental text) [49–51]. Through
international collaborative efforts, additional families with
de novo EBF3 variants were identified with similar pheno-
types [24–26].
A de novo double nucleotide substitution in SYN3
(c.1444_1445delinsTT; p.Pro481Leu), encoding synapsin
III, was found in a proband with DD, seizures, atrophy
of the cerebellar vermis, hypotonia, and a movement
disorder (Fig. 3b). SYN3 is a member of the synapsin
gene family, which includes SYN1 and SYN2, and plays a
major role in dopamine regulation [52]. MECP2 overex-
pression has been shown to result in upregulation
of SYN3 expression [53]. Taken together with the role
of dopamine signaling in epileptogenesis [54], we
hypothesize that the observed features of epilepsy and
DD in this patient, might be associated with the de novo
dinucleotide variant in SYN3. Finally, we identified denovo missense variants in ATAD3A (MIM 617183) and
EMC1 (MIM 616875) and additional collaborative efforts
supported these as disease genes with both monoallelic
and biallelic pathogenic variants [20, 22].
Potential mosaicism in parents
In a multiplex family of Arab descent, in which three of
five siblings have immunodeficiency, the clinical labora-
tory sequenced the first sibling without identifying a
molecular diagnosis. Therefore, we transferred the first
sibling’s WES data to BHCMG and offered WES to the
other two affected family members and parents. This
approach facilitated the examination of rare shared
variants among three affected siblings and led to the
detection of potential mosaic SNVs in the father. We iden-
tified a heterozygous variant c.1573G >A (p.Glu525Lys) in
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit delta (PIK3CD, MIM 602839) shared by the three
affected siblings and inherited from their apparently
ab
d
c
Fig. 3 Location of DHX30 and GNB5 variants, dinucleotide variants culled from WES data and UPD. a Variants identified in DHX30 and GNB5 are
located in specific protein domains. b Sanger confirmation of a de novo dinucleotide variant in SYN3. c The B-allele frequency extracted from
WES data in the patient with the homozygous SLC1A4 variant showed a single region of AOH in the genome (chromosome 2), suggestive of
uniparental disomy (UPD) of chromosome 2. d Segregation analysis of the SLC1A4 homozygous variant did not conform to Mendelian expectations
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cause an autosomal dominant form of immunodeficiency
[55]. To assess possible mosaicism in the father, we calcu-
lated the ratio of variant to total reads: 6/38 (15%). This
ratio significantly deviates from the expected 50% of
variant to total reads (p value 0.003). The same calcu-
lation in the three affected siblings yielded ratios of
20/53 (37%), 37/68 (54%), and 87/204 (42%), all of
which were not significantly different from the ex-
pected 50% of variant to total reads (p value 0.241,
0.731, and 0.164, respectively). This suggested possible
mosaicism in the father, whose post-WES clinical work-up
revealed mild laboratory signs of immunodeficiency
(with mild reduction of NK cell cytotoxicity) comparedto his severely affected children (Table 1, Additional file 3:
Table S2) [56].
Biallelic or hemizygous variants in genes known for
recessive disease traits
Homozygous or compound heterozygous variants were
detected in six recently described or well established dis-
ease genes: SLC13A5 (epileptic encephalopathy, MIM
615905); FBXL4 (mitochondrial DNA depletion syn-
drome 13, MIM 615471); ZNF335 (microcephaly in a
single family, MIM 615095); SLC1A4 (spastic tetraplegia,
thin corpus callosum, and progressive microcephaly,
MIM 616657); TRAPPC11 (limb girdle muscular dys-
trophy type 2S, MIM 615356); and ABCA4 (cone-rod
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identified in two known X-linked disease genes: NAA10
(Ogden syndrome, ID and long QT, MIM 300855); and
DDX3X previously associated with X-linked ID (MIM
300958) (Table 1, Additional file 3: Table S2) [41, 57–65].
The homozygous missense variant identified in
SLC1A4, encoding solute carrier family 1 (glutamate/
neutral amino acid transporter), member 4, did not fol-
low the expected Mendelian pattern of inheritance, since
only the father carried the variant. The cSNP array data,
which are performed as part of the clinical exome ana-
lysis, were integrated with calculated B allele frequency
information from WES data [38] and showed absence of
heterozygosity (AOH) limited to chromosome 2 and
encompassing almost the entire chromosome, indicating
paternal uniparental disomy with reduction of the vari-
ant to homozygosity as the responsible molecular mech-
anism (Fig. 3c, d).
Biallelic variants in novel and candidate recessive disease
genes
The parallel computational algorithm for detecting rare
homozygous stop-gain mutations from “bulk data” (i.e.
~5000 research exomes in the BHCMG database, includ-
ing this pilot study), identified a rare homozygous stop-
gain mutation in GNB5 (MIM 617182) in a study
participant with DD, hypotonia, retinopathy, and Mobitz
type I atrioventricular block (Fig. 3a). A homozygous
splice site variant (c.249 + 3 A > G) in GNB5 was de-
tected in two affected siblings from the clinical diagnos-
tic laboratory exhibiting DD/ID, nystagmus, and sinus
node dysfunction. GNB5 encodes the Gβ5 protein, a
guanine nucleotide-binding protein and a member of the
signal-transducing G protein β subunit family. Additional
participants with pathogenic variants in this disease gene
were subsequently identified [21].
Recessive variants were found in novel (MIPEP and
TANGO2) [19, 23, 66] as well as candidate genes:
USP19, NRXN3, and ACOT1 (Table 1; Additional file 3:
Table S2). Each of these was encountered in only one
family. USP19, found in a proband with epileptic
encephalopathy, DD, and hypotonia, encodes ubiquitin-
specific protease 19, which is involved in the regulation
of ataxin 3 (spinocerebellar ataxia, MIM 109150)
and interacts with DOCK7 (epileptic encephalopathy,
MIM 615859) and USP7 (autism spectrum disorder)
(Additional file 2: Figure S2) [67–69]. NRXN3 encodes a
member of the neurexin family of which NRXN1 is asso-
ciated with Pitt-Hopkins-like syndrome 2 (MIM 614325)
[70–72] and ACOT1 is involved in lipid metabolism
(Additional file 4: Supplemental text). Finally, we identi-
fied compound heterozygous SNVs in MIPEP (MIM
617228) and homozygous SNVs in TANGO2 (MIM
616878) and found additional evidence for pathogenicitythrough collaboration [19, 23]. Combinations of SNVs
and CNVs on alleles inherited in trans have been en-
countered in both of these genes, underscoring the po-
tential utility of WES in identifying CNVs (including
single exon deletions) as well as UPD.
Dual molecular diagnoses in known genes
A dual molecular diagnosis [8] was established in two
probands. The analysis of trio WES data revealed
both compound heterozygous variants in PMPCA and a
de novo variant in KCND3 in an individual with DD,
ataxia, epilepsy, Hirschsprung disease, and abnormal
mitochondrial function (Complex I and III deficiency).
In another family, quad WES analysis identified a pater-
nally inherited heterozygous missense variant of un-
known significance in SCN1B, the gene for Brugada
syndrome 5 (MIM 612838) [73], and compound hetero-
zygous changes in POLR1C, segregating in two affected
siblings (Table 1, Additional file 3: Table S2, Additional
file 4: Supplemental text). At the time of the initial clin-
ical exome analysis, neither PMPCA nor POLR1C were
associated with spinocerebellar ataxia and leukodystro-
phy, respectively. On the other hand, the clinical exome
laboratory did report both KCND3 (MIM 607346) [74]
and SCN1B (MIM 612838) as potential contributory var-
iants for the patients’ manifested phenotypes. Albeit, the
clinical features of the patients’ phenotypes could not be
completely explained by the changes in the KCND3 and
SCN1B genes, and both cases were subsequently en-
rolled into our pilot study. Our research analysis priori-
tized both the PMPCA (MIM 613036) and POLR1C
(MIM 610060) genes along with KCND3 and SCN1B as
potential contributory variants prompted by recent
publications, which uncovered their roles in human
disease [75, 76]. Of note, POLR1C was described in 2011
to cause recessive Treacher Collins syndrome (MIM
248390), however the patient’s clinical features were not
matching those of Treacher Collins syndrome, poten-
tially complicated by the blended phenotype due to the
dual molecular diagnosis [77].
Discussion
We developed and implemented a workflow for: (1) the
collection of new WES cases; (2) generation of add-
itional data and analyses resources; and (3) application
of further data filtering and adjuvant analysis methods to
discover novel and candidate disease genes. This work-
flow and the data generated were used to optimize po-
tential molecular diagnoses of Mendelian disease traits
in clinical exome cases for which an initial molecular
diagnosis was not achieved. This pilot study investigated
74 families and in 27 families (36%) identified a pre-
dicted damaging variant in a known or novel gene. If
one considers damaging variants in candidate genes that
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the cumulative rate of potential molecular diagnoses in
this pilot cohort of unsolved clinical exomes would be
51% (38/74). A particular phenotype, such as the pres-
ence or absence of ID, did not significantly influence the
rate of diagnosis; i.e. a potential molecular diagnosis was
achieved in 54.2% (32/59) of cases with DD/ID and
42.9% (6/14) cases without DD/ID (p value = 0.05;
Additional file 5: Table S3).
Beyond the impact on diagnosis, potential prognostic
information, and genetic counseling, several of the newly
established molecular diagnoses had implications for
medical management. Examples include acetazolamide
treatment for CACNA1A mutation, surveillance for
arrhythmias in GNB5 and TANGO2, and mitochondrial-
specific surveillance for cardiac, renal, and liver involve-
ment in FBXL4. For patients with the SCN1B variant,
current practice guidelines suggest treatment with iso-
proterenol as a first-line agent for electrical storm
(ventricular fibrillation) and consideration of an implant-
able cardioverter defibrillator (ICD) to prevent sudden
death [78]. In a recent study applying WES and CNV
testing in clinically diagnosed primary immune defi-
ciency diseases (PIDD), a molecular diagnosis was
achieved in about 40% of unrelated probands; clinical
diagnosis was revised in about half (60/110) and man-
agement was directly altered in nearly one-quarter of
families based on molecular findings [56].
In about half (12/27, 44.4%) of the families, diagnosed
by a known or novel disease gene, the same diagnosis
was achieved independently of the research analyses as
part of the routine reanalysis of WES data by the clinical
exome laboratory based on recent gene discoveries
(Table 1). The combined efforts of the clinical and
research laboratories have led to multiple reports of
novel disease genes, most of which are described in
much greater phenotypic and molecular detail in inde-
pendent publications (PURA, TANGO2, EMC1, GNB5,
ATAD3A, MIPEP, and EBF3) [18–26]. Since all of these
discoveries included cases from the 74 in our pilot study
and can be attributed to combined efforts between the
clinical and research laboratories, they are included in
the overall stated molecular diagnostic yield of 36%.
Our study demonstrates that an increase in the
molecular diagnostic yield can be achieved through sys-
tematic and comprehensive reanalysis of clinical exome
data. Of 74 cases with non-diagnostic clinical exomes, a
molecular diagnosis was achieved in 30/63 trios (47.6%),
4/6 singleton cases (66.7%), 1/1 multiplex family involv-
ing three affected siblings, and 3/4 (75%) quartet families
(Additional file 6: Table S4). This increased diagnostic
yield beyond clinical WES may be attributed to: (1) the
rapid pace of Mendelian gene discovery; (2) the use of
trio sequencing; and (3) the extensive research reanalysisand implementation of novel tools for identification of
de novo and CNV variants. Vigorous collaboration be-
tween clinical and research efforts can enhance diagnos-
tic yield and fuel novel disease gene discovery. For
instance, the clinical exome laboratories’ standard oper-
ating procedure for exome analysis and variant interpret-
ation adheres to current ACMG guidelines, which
include recommendations for the reporting of patho-
genic variants, likely pathogenic variants, and variants of
unknown significance (VUS) in known (established) dis-
ease genes [27]. These stringent criteria do not provide
for reporting of novel disease genes at the time of initial
discovery, as by definition they cannot be considered
pathogenic or likely pathogenic until a causal relation-
ship between variation at a particular locus and disease
has been firmly established. Thus, novel variation and
novel disease genes are best studied in a research envir-
onment. In our study, the pursuit of novel disease genes
for rare disease benefits from a tremendous resource:
the combined exome variant dataset from over 15,000
cases referred to either the clinical exome laboratory or
the BHCMG research laboratory. Research studies also
support reporting of novel disease genes at the time of
initial discovery, an important step toward gaining suffi-
cient evidence to meet ACMG guidelines for reporting
by a diagnostic laboratory. Additionally, as certain tools
are developed and validated in a research setting and are
honed to better efficiency, they are frequently translated
into the clinical pipeline; GeneMatcher, developed by
the BHCMG, is one such example [13, 14].
In this study, trio-WES analysis combined with de
novo variant and CNV detection were invaluable for
achieving an improved molecular diagnostic rate. The
addition of parental samples (i.e. trio analysis) led to mo-
lecular diagnoses in 47.6% (30/63) of cases for which
proband-WES was non-diagnostic. Analysis of trio-WES
data supports the efficient identification of de novo and
compound heterozygous variants, leading to improved
analysis efficiency across all inheritance models. In an at-
tempt to limit false-positive calls, we required that both
parents have at least ten reference reads. Thus, a limita-
tion to our analysis is that regions with poor coverage in
either or both parents were parsed during variant filter-
ing. Taking these regions/genes into account by flagging
them in the bioinformatics pipeline and performing
Sanger confirmation of any candidate variants at these
loci may further optimize identification of candidate de
novo variants. As the cost of WES continues to fall, we
anticipate that trio-WES may ultimately be favored over
proband-WES in the clinical setting of a sporadic sus-
pected genetic disease.
Trio analysis also supported the use of a newly devel-
oped tool, DNM-Finder (https://github.com/BCM-Lups
kilab/DNM-Finder). In our study, 27% of the pathogenic
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lysis can also increase the molecular diagnostic yield
over that attained by studies of the proband alone.
This is due, in part, to being able to more readily
detect by computational filtering de novo variants
(Additional file 2: Figure S1). All DNA was extracted
from blood or saliva samples in this study; however,
detection of mosaicism may be enhanced by including
concurrent analyses of more than one lineage: ectodermal
(buccal swab, hair), mesodermal, and/or endodermal
(blood, saliva). The degree of mosaicism correlates
with the timing of mutation, cell migration and desig-
nation during development, and tissue-specific growth
profile [79]. Taking into account such considerations
is important to guide the detection of mosaicism.
Additionally, compound heterozygosity is more readily
detected.
Analysis of all modes of inheritance and comprehensive
review beyond the first identified potential pathogenic
variant allowed for identification of dual molecular diag-
noses in two cases (e.g. PMPCA and KCND3; POLR1C
and SCN1B), consistent with previous reports of diagnoses
in 5–7% of molecularly diagnosed cases [3, 5, 8, 9, 56, 80,
81]. These cases underscore the need for a systematic and
comprehensive approach to exome variant analysis for all
possible modes of inheritance as well as an updatedTable 2 Lessons learned that may increase the molecular diagnostic
Lesson Learned Ex
A) Collaboration between research and clinical laboratories Sh
pa
B) Facilitating research collaborations including local and international
efforts
Ge
th
C) Ancillary approaches to enhance molecular diagnostic rate:
1) Detection of AOH and CNVs from WES
2) Annotation of single exon genes
3) Analyze intronic variants (including those in the unfiltered vcf files)
4) Optimization of the bioinformatic filters
5) Look for in trans inheritance of SNVs and CNVs
6) Increase fidelity of calling dinucleotide substitutions
1)
2)
3)
4)
5)
6)
D) Ancillary approaches for non-conclusive WES:
1) Consider dual molecular diagnoses
2) Analyze additional family members
3) Look for parental mosaicism
4) Identify homozygous stop-gain SNVs from bulk data to identify
additional affected individuals
1)
2)
3)
4)
E) Consideration of different inheritance patterns and variant types at a
single locus
1) AR, AD
2) AD, CNV del
3) AR, CNV del
4) XLR, CNV dup
5) AD, Tandem repeats
6) AR, AR
1)
2)
3)
4)
5)
6)
aThe molecular diagnosis in these genes had direct implications for clinical manage
AD autosomal dominant, AOH absence of heterozygozity, AR autosomal recessive, d
variants, WES whole exome sequencing, WGS whole genome sequencing, XLR X-linkliterature review [12]. This is especially true of cases in
which we observe apparent “phenotypic expansion” (clin-
ical features previously unreported in association with the
gene) or unexpected clinical severity [8].
Ancillary approaches to “bulk data” reanalysis were
shown to enhance the molecular diagnostic rate. These
include the examination of rare homozygous stop-gain
SNVs, extraction of copy number information from the
WES data to search for regions of absence of heterozy-
gosity (AOH) (i.e. ABCA4 and FBXL4) and assessing
UPD (i.e. SLC1A4) and small deletion CNVs that might
escape detection by CMA (Fig. 3c, Table 2, Additional
file 2: Figure S3) [19, 38]. We also underscore the im-
portance of capturing single-exon genes on WES plat-
forms (PURA, GSPT2); these can be challenging as they
are often rich in GC content, similar to the first exon of
multiexonic genes [82].
Our study highlights the limitations of different WES
data variant calling pipelines. The research laboratory
opts for less stringent filtering of variants, which allows
identification of intronic variants located farther from
the splice site (i.e. ABCA4); albeit, this increases the
number of variants to be investigated and consequently
time taken for analysis. For instance, clinical WES
did not reveal a conclusive molecular variant in a pro-
band who presented with cone-rod dystrophy fromyield from unsolved clinical exomes
amples
aring data, open communication of findings, access to additional
tients with damaging variants
neMatcher for the identification of unrelated affected individuals with
e same novel disease
ABCA4, SLC1A4, TANGO2, FBXL4
PURA, GSPT2
TRAPPC11
ABCA4, NRXN3
TANGO2a, MIPEP
SYN3
PMPCA and KCND3; POLR1C and SCN1Ba
SLC13A5, NAA10
PIK3CD
GNB5a
ATAD3A, EBF3, EMC1, GSPT2, NALCN, GUCY2C
EBF3, PURA, ZBTB20
NRXN3
GSPT2
CACNA1Aa
POLR1C
ment
el deletion, dup duplication, CNV copy number variation, SNV single nucleotide
ed recessive
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research bioinformatics pipeline detected a homozygous
intronic frameshift deletion, which possibly could
explain the phenotype. The inherited deletion was more
common in the South Asian population (seen 14 times
on ExAC filtered variants). We also identified shared
limitations between both pipelines, i.e. dinucleotide sub-
stitutions called as two separate variants. Our pilot study
reflects the strength of collaborative efforts and iterative
analyses between clinical and research teams for the
optimization of computational pipelines to analyze WES
data and further understand the genetic architecture
underlying disease, both Mendelian disease and com-
mon/complex traits (Table 2).
This study confirms and extends our understanding of
the relationship between variation at a locus and disease
expression. We identified examples of genes for which
different variant alleles are associated with either a dom-
inant or a recessive disease trait (e.g. EMC1, ATAD3A,
NALCN, and GUCY2C) [20, 22, 43, 83–86]. Other genes
presented with recessive changes or de novo SNVs/
CNVs underlying different phenotypes (e.g. NRXN3) for
which heterozygous CNVs have previously been reported
with disease [87]. Several genes were found to have
de novo SNV and CNV alleles: EBF3, GSPT2, PURA,
and ZBTB20 [18, 23, 26, 39, 50, 51, 88–90]. This
phenomenon can be exemplified by recent reports of
glutamate receptor, ionotropic, delta 2 (GRID2, MIM
616204), which can contribute to neurodevelopmental
disorders and ataxia through recessive and de novo
SNVs as well as homozygous and de novo partial CNV
deletions (Table 2) [91–95]. Furthermore, CACNA1A
gene function can be altered either by de novo SNVs or
trinucleotide repeat expansion (CAG) to manifest with a
broad range of neurological disorders [42, 96, 97]. Yet
another class of genes can present with distinct disorders
due to allelic heterogeneity, e.g. POLR1C associated with
recessive hypomyelinating leukodystrophy 11 (MIM
616494) and recessive Treacher Collins syndrome 3
(MIM 248390) [76] and illustrate allelic affinity wherein
different clinical disease phenotypes are due to different
alleles at the same locus [98]. In addition, compound
heterozygous SNV and CNV alleles have been exempli-
fied in other patients exhibiting MIPEP and TANGO2
associated phenotypes (Table 2) [19, 23, 66]. These find-
ings of different variant allele types and combinations
thereof underscore the notion that defining potential
causative alleles necessitates consideration of all variant
types (SNV, indels, and CNV) and a multitude of poten-
tial genetic mechanisms (e.g. alleles causing dominant
traits while other alleles cause recessive disease traits,
EMC1 and ATAD3A [20, 22]) and inheritance patterns
while seeking answers for the genetic basis of Mendelian
phenotypes.These data dramatically illustrate how genetic disease
can be driven by rare recent variants introduced into a
family, further supporting the clan genomics hypothesis
[99]. The clan genomics model could explain how the
same gene may contribute to disease by either de novo
and/or recessive SNVs and/or CNVs. De novo events
arise in each generation from the failure of DNA repair
or replication errors [100]. Rare de novo events with
strong mutation effects (i.e. rare variants, predicted to
be deleterious) may manifest as disease in the first gen-
eration [100, 101], in contrast to weaker variant alleles
which require a second pathogenic allele or reduction to
homozygosity in order to manifest as a trait or disease in
subsequent generations (i.e. ATAD3A, EMC1, GUCY2C,
and NALCN genes) [20, 22, 43, 83–86]. Remarkably,
some carrier states for recessive disease may raise the
susceptibility for a common, complex trait as age
progresses, as demonstrated by heterozygous SNVs ob-
served in ABCA4, also known as ABCR, (MIM 153800),
CFTR (MIM 167800), and LDLR (MIM 143890) genes
leading to age-related macular degeneration, pancrea-
titis, and familial hypercholesterolemia, respectively [63,
99, 102–107]. Taken together, the heterogeneity of phe-
notypes, different inheritance patterns, and different
kinds of variants (SNVs or CNVs) presented in our study
may lead to an enhanced understanding of a unified gen-
etic model for human disease [99].
As the price of WES falls, trio analysis will be more
efficient for sporadic traits than singleton analysis, in
that it allows for detection of de novo variants and phas-
ing of compound heterozygous variants prior to Sanger
validation. This enhances detection of relevant variants
in known genes and serves to catalyze novel gene dis-
covery. Based on our study, we propose a workflow for
the management of non-conclusive singleton clinical
WES (Table 2, Additional file 2: Figure S4). This work-
flow intends to investigate the many possible scenarios
that could be encountered when clinical exomes are
non-productive for a specific molecular diagnosis. These
include: (1) de novo missense SNVs; (2) dual molecular
diagnoses; (3) multiple affected family members; (4)
potential parental mosaicism; (5) in trans inheritance of
SNVs and CNVs; (6) loosening the default parameters of
bioinformatics filters for parsing variants; and (7) poten-
tial intronic unfiltered variants on variant calling files.
A study that applied WGS to 50 clinical cases that
remained unsolved by genomic studies, i.e. in which pro-
bands initially had non-conclusive clinical microarrays
and WES, revealed an additional molecular diagnostic
yield of 42%. This 42% molecular diagnostic yield was
driven mainly by de novo SNVs and CNVs impacting
the coding regions [108]. In the current research
reanalysis of 74 clinical exomes, by implementing WES
reanalysis and augmentation with additional family
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diagnosis yield (36%) of unsolved exomes and even
higher increased rate (51%) if potential candidate genes
are considered. These pilot studies data (50 WGS versus
74 WES + reanalysis) suggest that currently WGS offers
no significant advantage to WES and reanalysis when it
comes to increasing molecular diagnostic yield from
unsolved clinical exomes. Nevertheless, the diagnostic
yield by WGS may potentially be increased further by
the development of new bioinformatic algorithms to
detect intronic variants or variants in regulatory regions
as well as structural variations followed by further func-
tional characterization. Future studies comparing WGS
versus WES performances for diagnostic yield should
use both of these techniques in parallel while also taking
other parameters (coverage and cost) into account.
Conclusion
We have demonstrated that systematic study of “unsolved
clinical exomes” can provide a rich resource for Mendelian
gene discovery and that reanalysis of data coupled with
incorporation of additional family member WES data
can improve the molecular diagnostic rate. These re-
search studies can, in turn, provide the basis for improv-
ing interpretive algorithms for clinical WES analyses
(Additional file 2: Figure S4). Our data additionally
highlight the remarkable contribution of new mutation
to disease including blended phenotypes resulting from
dual molecular diagnoses [3, 5, 8]. Speculation based on
these pilot study data suggests that if one considers the
25–30% molecular diagnostic rate achieved by initial
clinical exome analyses, in combination with the 51%
rate found in these pilot research studies of unsolved
clinical exomes, genomic analyses by WES have the
potential to identify a rare variant and gene that implicate
a molecular diagnosis which could impact clinical decisions
in ~ 63 (25% + [75%*51%]) to 66% (30% + [70%*51%]) or
the majority of cases.Additional files
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